[Edaily Reporter KIM SAE-MI ] #SAMSUNG EPIS HOLDINGS announced on the 21st that its subsidiary, Samsung Bioepis, has signed an exclusive supply agreement for “SB12” through the Productive Development Partnership (PDP) initiative led by the Brazilian government.

SB12 is a biosimilar of “Soliris” (active ingredient: eculizumab), a treatment for rare diseases developed by U.S.-based Alexion. Eculizumab is a monoclonal antibody that inhibits the complement protein C5 and is used to treat rare diseases such as paroxysmal nocturnal hemoglobinuria (PNH).

This contract was secured through the Brazilian government-led PDP initiative. PDP is a public-private partnership program promoted by the Brazilian government to ensure the stability of the pharmaceutical supply and strengthen local production capabilities.

Samsung Bioepis plans to enter into additional supply agreements in the future to fulfill this contract. Specific terms, such as the exact supply volume and unit price, have not yet been determined.

Samsung Bioepis stated, “We plan to issue a follow-up disclosure either when additional details are finalized in future supply contracts and a disclosure obligation arises, or within one month thereafter.”

The scheduled date for the re-disclosure is the 20th of next month.